SCHEMBL3337378

SCHEMBL3337378

O=C(NNc1nc(-c2cccc([N+](=O)[O-])c2)cs1)c1ccccc1F

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 4/20 0.62
MEN1 O00255 10/20 0.58
KMT2A Q03164 10/20 0.58
MAPT P10636 6/20 0.58
ALDH1A1 P00352 5/20 0.58
HTT P42858 4/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
VCP P55072 1/20 0.58
RAB9A P51151 2/20 0.57
GAA P10253 1/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
NPC1 O15118 1/20 0.55
MAOA P21397 2/20 0.55
MAOB P27338 2/20 0.55
BAZ1A Q9NRL2 1/20 0.53
LMNA P02545 1/20 0.52
HDAC3 O15379 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3339288 0.88 MEN1 (0.73) CSNK2A1MEN1KMT2AMAPTALDH1A1
SCHEMBL3343901 0.84 MEN1 (0.77) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL3338830 0.82 MEN1 (0.73) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL3338847 0.78 MEN1 (0.63) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL10808167 0.77 BAZ1A (0.79) CSNK2A1MEN1KMT2AMAPTALDH1A1
SCHEMBL10922701 0.77 KMT2A (0.72) CSNK2A1MEN1KMT2AMAPTALDH1A1
SCHEMBL15688998 0.77 MEN1 (0.87) CSNK2A1MEN1KMT2AMAPTALDH1A1
SCHEMBL10962764 0.76 KMT2A (0.74) CSNK2A1MEN1KMT2AMAPTALDH1A1
SCHEMBL4799557 0.76 CSNK2A1 (0.52) CSNK2A1MEN1KMT2AMAPTALDH1A1
SCHEMBL24340403 0.75 KMT2A (0.69) CSNK2A1MEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA CSNK2A1 3011/4885MEN1 1886/4885KMT2A 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.